Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zydus Lifesciences Limited

https://www.zyduslife.com/index

Latest From Zydus Lifesciences Limited

Cipla's Advair Generic Debut In Sight, More Platform Deals On Radar Post Ethris

Cipla believes it is “pretty close” to approval for its Advair generic in the US, while another product, generic Abraxane, stands delayed currently. Following the deal with Ethris, which is progressing inhaled mRNA-based therapies, the company signals interest in platforms such as CAR-T as well.

Commercial Generic Drugs

Ibrance Generics Arrive In India, Patient Programs Add Free Drug Component

Pfizer’s Ibrance is set to lose exclusivity in the US only by 2027, but the Indian market is buzzing with activity as generics including from top-ranked drug maker Sun Pharma vie for a share of the pie. Competing CDK4/6 inhibitors are already available but can cut-price palbociclib versions alter market dynamics?

Generic Drugs Launches

Ibrance Generics Arrive In India, Patient Programs Add Free Drug Component

Pfizer’s Ibrance is set to lose exclusivity in the US only by 2027, but the Indian market is buzzing with activity as generics including from top-ranked drug maker Sun Pharma vie for a share of the pie. Competing CDK4/6 inhibitors are already available but can cut-price palbociclib versions alter market dynamics?

Commercial India

Differentiation Is Mantra As Amneal Targets $1bn By 2030 From Non-US Geographies

As Amneal makes its commercial debut in markets outside the US, Shyamakant Giri, MD and president, India and emerging markets, formulates a strategy based on differentiation and a targeted approach. From ‘theranostics’ to partnered products, he has multiple aces up his sleeves, Giri tells Scrip in an interview.

Commercial Leadership
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Cadila Healthcare
    • Zydus Pharmaceuticals USA
    • German Remedies
    • Zynesher Pharmaceuticals USA LLC
    • Nesher Pharmaceuticals Inc
    • Quimica e Farmaceutica Nikkho do Brasil Ltda
    • Bremer Pharma GmbH
    • Nippon Universal Pharmaceuticals
    • Zydus Discovery DMCC
    • Zydus Urosciences
    • Sentynl Therapeutics, Inc
    • Zydus Lifesciences Ltd
    • Cadila Healthcare Ltd.
    • Zydus Cadila
UsernamePublicRestriction

Register